

Zituvio[™] (sitagliptin) – New drug approval

- On October 20, 2023, <u>Zydus Lifesciences announced the FDA approval</u> of <u>Zituvio (sitagliptin)</u>, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
 - Zituvio is not recommended in patients with type 1 diabetes mellitus.
 - Zituvio has not been studied in patients with a history of pancreatitis. It is unknown
 whether patients with a history of pancreatitis are at increased risk for the development of
 pancreatitis while using Zituvio.
- Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and is also available under the brand name Januvia[®]. Zituvio shares the same indication as Januvia.
- Warnings and precautions for Zituvio include pancreatitis; heart failure; acute renal failure; hypoglycemia with concomitant use with insulin or insulin secretagogues; hypersensitivity reactions; severe and disabling arthralgia; and bullous pemphigoid.
- The most common adverse reactions (≥ 5%) with Zituvio use were upper respiratory tract infection, nasopharyngitis and headache. In the add-on to sulfonylurea and add-on to insulin studies, hypoglycemia was also more commonly reported in patients treated with Zituvio compared to placebo.
- The recommended dose of Zituvio is 100 mg orally once daily.
- Zydus Lifesciences' launch plans for Zituvio are pending. Zituvio will be available as 25 mg, 50 mg, and 100 mg tablets.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.